Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mipletamig
- Development stage
- Phase 1
- Lead developer
- Aptevo Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Mipletamig is a recombinant, bispecific T-cell engaging antibody developed by Aptevo Therapeutics. It targets both CD123 and CD3, redirecting the patient’s immune system to destroy leukemia cells expressing the surface antigen CD123. The drug is designed using Aptevo's ADAPTIR platform and features a unique CRIS-7 derived CD3 binding domain intended to reduce the likelihood and severity of cytokine release syndrome (CRS), a common complication with other bispecific antibodies. Mipletamig is administered intravenously and has received orphan drug designation for acute myeloid leukemia (AML). It is being investigated primarily as frontline therapy in combination with venetoclax and azacitidine for AML, but also in myelodysplastic syndromes (MDS) and other leukemias. Clinical trials have shown high remission rates with an improved safety profile compared to standard therapies[1][2][5][7][8].
- Other names
- APVO-436APVO436APVO 436
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on mipletamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mipletamig.